Dmitry A. Napalkov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dmitry A. Napalkov has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Anastasiya A. Sokolova
Sechenov First Moscow State Medical University (Sechenov University)
46 shared publications - Anna A. Kudrjavtseva
Sechenov First Moscow State Medical University (Sechenov University)
10 shared publications - Viktor Viktorovich Fomin
Russian Medical Academy of Continuous Professional Education
8 shared publications - Pavel M. Krupenin
Sechenov First Moscow State Medical University (Sechenov University)
7 shared publications - Alena I. Skripka
Sechenov First Moscow State Medical University (Sechenov University)
6 shared publications V. V. Fomin
I.M. Sechenov First Moscow State Medical University (Sechenov University)
6 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 22 (2) , 139-145
Use of an individual NT-proBNP value calculator in the diagnosis of heart failure with preserved ejection fraction
Aim. To develop an online calculator of individual NT-proBNP thresholds to diagnose heart failure with preserved ejection fraction (HFpEF) and to pilot it in clinical practice. Material and methods. At the first stage, an online calculator that computes a personalised NT-proBNP threshold based on age, sex, body mass index (BMI), estimated glomerular filtration rate (CKD-EPI), and the presence of atrial fibrillation was developed. A total of 128 patients (50% women; median age, 71 years) with HFpEF hospitalised at University Clinical Hospital No. 1, Sechenov University, between January and August 2024 were enrolled to validate the calculator. Diagnoses based on guideline-recommended NT-proBNP cutoffs were compared with diagnoses incorporating individualised thresholds from the calculator. Agreement between methods was assessed using Cohen’s kappa, and differences in diagnosis rates were evaluated with McNemar’s test. Results . When comparing diagnoses based on standard NT-proBNP thresholds with those using individualised values, the diagnosis changed in 38 cases (29.7%): HFpEF was established in 30 patients and excluded in 8. Cohen’s kappa was 0.35. The difference between approaches was statistically significant (p=0.0005). The greatest diagnostic discrepancies were observed in patients younger than 60 years and in those with BMI 30-34 kg/m² and ≥40 kg/m²; statistically significant differences in diagnosis frequency were found only for patients with BMI 30-34 kg/m² (k=0.38, p Conclusion. NT-proBNP remains a key biomarker in HFpEF diagnosis; however, patient sex, age, and comorbidities affect its circulating levels. We therefore propose using our online calculator to derive individualized NT-proBNP thresholds for HFpEF diagnosis to reduce diagnostic errors, initiate treatment in a timely manner, and avoid unnecessary medication.
- 17 June 2026
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 22 (2) , 139-145
Open AccessUse of an individual NT-proBNP value calculator in the diagnosis of heart failure with preserved ejection fraction
Aim. To develop an online calculator of individual NT-proBNP thresholds to diagnose heart failure with preserved ejection fraction (HFpEF) and to pilot it in clinical practice. Material and methods. At the first stage, an online calculator that computes a personalised NT-proBNP threshold based on age, sex, body mass index (BMI), estimated glomerular filtration rate (CKD-EPI), and the presence of atrial fibrillation was developed. A total of 128 patients (50% women; median age, 71 years) with HFpEF hospitalised at University Clinical Hospital No. 1, Sechenov University, between January and August 2024 were enrolled to validate the calculator. Diagnoses based on guideline-recommended NT-proBNP cutoffs were compared with diagnoses incorporating individualised thresholds from the calculator. Agreement between methods was assessed using Cohen’s kappa, and differences in diagnosis rates were evaluated with McNemar’s test. Results . When comparing diagnoses based on standard NT-proBNP thresholds with those using individualised values, the diagnosis changed in 38 cases (29.7%): HFpEF was established in 30 patients and excluded in 8. Cohen’s kappa was 0.35. The difference between approaches was statistically significant (p=0.0005). The greatest diagnostic discrepancies were observed in patients younger than 60 years and in those with BMI 30-34 kg/m² and ≥40 kg/m²; statistically significant differences in diagnosis frequency were found only for patients with BMI 30-34 kg/m² (k=0.38, p Conclusion. NT-proBNP remains a key biomarker in HFpEF diagnosis; however, patient sex, age, and comorbidities affect its circulating levels. We therefore propose using our online calculator to derive individualized NT-proBNP thresholds for HFpEF diagnosis to reduce diagnostic errors, initiate treatment in a timely manner, and avoid unnecessary medication.
- 17 June 2026
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 22 (2) , 197-203
Secondary arterial hypertension due to excessive vitamin D intake and hyperparathyroidism: a clinical case
This clinical case report describes the development of intoxication symptoms (nausea, muscle cramps, generalised weakness) and instability of blood pressure associated with long-term uncontrolled intake of high-dose vitamin D (up to 35,000 IU per week) in a 68-year-old female patient with comorbid conditions: secondary arterial hypertension, primary hyperparathyroidism, and chronic kidney disease stage C3a. Laboratory analysis revealed a typical triad of abnormalities: hypercalcemia (total calcium up to 2.82 mmol/L), elevated parathyroid hormone level (115.4 pg/mL), and a high serum 25(OH)D concentration (70.6 ng/mL). Key evidence of the iatrogenic nature of the symptoms was the complete resolution of complaints and normalisation of blood pressure on the previous antihypertensive therapy following discontinuation of vitamin D intake, as well as recurrence of symptoms upon resumption of vitamin D supplements, even at a lower dose (14,000 IU/day). A notable feature of this case is the development of toxic effects at a serum 25(OH)D level only slightly above the normal range, which underscores the importance of identifying adverse effects when prescribing therapy to patients with comorbidities. This observation highlights the necessity for thorough laboratory monitoring (calcium, parathyroid hormone, 25(OH)D, renal function parameters) prior to and during vitamin D supplementation, particularly in patients with hyperparathyroidism and chronic kidney disease.
- 17 June 2026
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 22 (2) , 197-203
Secondary arterial hypertension due to excessive vitamin D intake and hyperparathyroidism: a clinical case
This clinical case report describes the development of intoxication symptoms (nausea, muscle cramps, generalised weakness) and instability of blood pressure associated with long-term uncontrolled intake of high-dose vitamin D (up to 35,000 IU per week) in a 68-year-old female patient with comorbid conditions: secondary arterial hypertension, primary hyperparathyroidism, and chronic kidney disease stage C3a. Laboratory analysis revealed a typical triad of abnormalities: hypercalcemia (total calcium up to 2.82 mmol/L), elevated parathyroid hormone level (115.4 pg/mL), and a high serum 25(OH)D concentration (70.6 ng/mL). Key evidence of the iatrogenic nature of the symptoms was the complete resolution of complaints and normalisation of blood pressure on the previous antihypertensive therapy following discontinuation of vitamin D intake, as well as recurrence of symptoms upon resumption of vitamin D supplements, even at a lower dose (14,000 IU/day). A notable feature of this case is the development of toxic effects at a serum 25(OH)D level only slightly above the normal range, which underscores the importance of identifying adverse effects when prescribing therapy to patients with comorbidities. This observation highlights the necessity for thorough laboratory monitoring (calcium, parathyroid hormone, 25(OH)D, renal function parameters) prior to and during vitamin D supplementation, particularly in patients with hyperparathyroidism and chronic kidney disease.
- 13 June 2026
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 25 (5)
Nephroprotective effect of sodium-glucose cotransporter-2 inhibitors in patients with atrial fibrillation and chronic kidney disease
Aim. To evaluate the changes of renal function during treatment with sodium-glucose cotransporter-2 (SGLT-2) inhibitors in patients with atrial fibrillation (AF) and chronic kidney disease (CKD). Material and methods. A total of 100 patients with AF and stage 3-4 CKD were included. Serum creatinine levels, creatinine clearance (CrCl) according to the Cockcroft-Gault equation, and glomerular filtration rate (GFR) using the CKD-EPI equation were assessed. A decrease in GFR ≥20%, a doubling of creatinine levels, and the development of acute kidney injury (AKI) were analyzed. Results. After 18 months, the GFR in the study group averaged 10,1 (95% confidence interval: 3,6; 16,7) ml/min/1,73 m 2 higher than in the control group. In patients with stage C3B CKD, the GFR level increased by 4,3±10,5 ml/min/1,73 m 2 from baseline. Patients taking SGLT-2 inhibitors had an increased risk of progression from stage C3B CKD to stage C3A: odds ratio (OR) =0,53; 95% confidence interval: 0,42; 0,67. Differences in kidney function were observed only with renin-angiotensin system inhibitors. No doubling of creatinine levels or development of acute kidney injury was observed. There were no differences between groups in the incidence of a decrease in GFR ≥20%. Conclusion. The renoprotective effect of SGLT-2 inhibitors is maintained in patients with combined AF and CKD, especially in patients with CKD stage C3B.
- 13 June 2026
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 25 (5)
Nephroprotective effect of sodium-glucose cotransporter-2 inhibitors in patients with atrial fibrillation and chronic kidney disease
Aim. To evaluate the changes of renal function during treatment with sodium-glucose cotransporter-2 (SGLT-2) inhibitors in patients with atrial fibrillation (AF) and chronic kidney disease (CKD). Material and methods. A total of 100 patients with AF and stage 3-4 CKD were included. Serum creatinine levels, creatinine clearance (CrCl) according to the Cockcroft-Gault equation, and glomerular filtration rate (GFR) using the CKD-EPI equation were assessed. A decrease in GFR ≥20%, a doubling of creatinine levels, and the development of acute kidney injury (AKI) were analyzed. Results. After 18 months, the GFR in the study group averaged 10,1 (95% confidence interval: 3,6; 16,7) ml/min/1,73 m 2 higher than in the control group. In patients with stage C3B CKD, the GFR level increased by 4,3±10,5 ml/min/1,73 m 2 from baseline. Patients taking SGLT-2 inhibitors had an increased risk of progression from stage C3B CKD to stage C3A: odds ratio (OR) =0,53; 95% confidence interval: 0,42; 0,67. Differences in kidney function were observed only with renin-angiotensin system inhibitors. No doubling of creatinine levels or development of acute kidney injury was observed. There were no differences between groups in the incidence of a decrease in GFR ≥20%. Conclusion. The renoprotective effect of SGLT-2 inhibitors is maintained in patients with combined AF and CKD, especially in patients with CKD stage C3B.
- Open Access
- 31 March 2026
- Published by ECO-Vector LLC (Publications) in I.P. Pavlov Russian Medical Biological Herald
- Vol. 34 (1) , 127-134
Syncope in an adult patient with comorbidity: from syndrome to diagnosis of pertussis infection
BACKGROUND: In recent years, the morbidity with pertussis has shown a significant growth among both children and adults worldwide. Complications and fatalities are more commonly recorded among children, although adults, especially those with underlying pathology, are also at risk. In addition, in adult patients, the disease is characterized by attenuated forms and comorbidities, which hampers timely diagnosis and treatment and contributes to the development of complications. This article presents a clinical case of pertussis in a patient with morbid obesity, uncontrolled hypertension, impaired glucose tolerance, vasomotor rhinitis, and severe obstructive sleep apnea syndrome (OSAS). A notable feature of this case is the development of bettolepsy a syncopal state occurring at the height of a coughing fit, which resulted in trauma to the patient. The absence of a prodromal period of syncope and the presence of several significant comorbidities necessitated a comprehensive diagnostic search. A medical history revealed contact with children with pertussis. Serological testing confirmed pertussis infection. Instrumental studies, including cardiorespiratory sleep monitoring, electroencephalography, magnetic resonance imaging of the head, duplex scanning of the brachiocephalic arteries, and computed tomography of the chest, were performed. Based on these results, cardiac and neurological causes of syncope were excluded, suggesting pertussis infection as the cause of syncope. Prescribed therapy included cough suppressants, reinstatement of CPAP therapy after consultation with an otolaryngologist, and nasal breathing correction for OSAS, which led to improvement in the patient's condition. CONCLUSION: This case highlights the need to include pertussis in the differential diagnosis of adult patients with a persistent cough, even in the absence of the classic clinical picture. This is especially important in a patient with comorbidities, such as OSAS, which can aggravate the course of pertussis and lead to life-threatening complications. Timely diagnosis and appropriate treatment are essential to prevent an adverse outcome.
- 31 March 2026
- Published by ECO-Vector LLC (Publications) in I.P. Pavlov Russian Medical Biological Herald
- Vol. 34 (1) , 127-134
Open AccessSyncope in an adult patient with comorbidity: from syndrome to diagnosis of pertussis infection
BACKGROUND: In recent years, the morbidity with pertussis has shown a significant growth among both children and adults worldwide. Complications and fatalities are more commonly recorded among children, although adults, especially those with underlying pathology, are also at risk. In addition, in adult patients, the disease is characterized by attenuated forms and comorbidities, which hampers timely diagnosis and treatment and contributes to the development of complications. This article presents a clinical case of pertussis in a patient with morbid obesity, uncontrolled hypertension, impaired glucose tolerance, vasomotor rhinitis, and severe obstructive sleep apnea syndrome (OSAS). A notable feature of this case is the development of bettolepsy a syncopal state occurring at the height of a coughing fit, which resulted in trauma to the patient. The absence of a prodromal period of syncope and the presence of several significant comorbidities necessitated a comprehensive diagnostic search. A medical history revealed contact with children with pertussis. Serological testing confirmed pertussis infection. Instrumental studies, including cardiorespiratory sleep monitoring, electroencephalography, magnetic resonance imaging of the head, duplex scanning of the brachiocephalic arteries, and computed tomography of the chest, were performed. Based on these results, cardiac and neurological causes of syncope were excluded, suggesting pertussis infection as the cause of syncope. Prescribed therapy included cough suppressants, reinstatement of CPAP therapy after consultation with an otolaryngologist, and nasal breathing correction for OSAS, which led to improvement in the patient's condition. CONCLUSION: This case highlights the need to include pertussis in the differential diagnosis of adult patients with a persistent cough, even in the absence of the classic clinical picture. This is especially important in a patient with comorbidities, such as OSAS, which can aggravate the course of pertussis and lead to life-threatening complications. Timely diagnosis and appropriate treatment are essential to prevent an adverse outcome.
- Open Access
- 14 February 2026
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 97 (12) , 1018-1022
A clinical case of erythromelalgia in a patient comorbid with antiphospholipid syndrome
The article presents a clinical case of secondary erythromelalgia in a comorbid patient with antiphospholipid syndrome, accompanied by burning pain, hyperemia and swelling of the lower extremities. A comprehensive examination involving a neurologist, dermatologist, and rheumatologist was conducted to establish the diagnosis and select the optimal therapy. Significant clinical improvement in the patient's condition is demonstrated against the background of pregabalin therapy. The importance of a multidisciplinary approach and the difficulty of diagnosis due to the lack of specific examination methods and insufficient awareness of doctors about this disease are emphasized. The described case demonstrates the need for a personalized approach to managing patients with erythromelalgia to improve their quality of life.
- 14 February 2026
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 97 (12) , 1018-1022
Open AccessA clinical case of erythromelalgia in a patient comorbid with antiphospholipid syndrome
The article presents a clinical case of secondary erythromelalgia in a comorbid patient with antiphospholipid syndrome, accompanied by burning pain, hyperemia and swelling of the lower extremities. A comprehensive examination involving a neurologist, dermatologist, and rheumatologist was conducted to establish the diagnosis and select the optimal therapy. Significant clinical improvement in the patient's condition is demonstrated against the background of pregabalin therapy. The importance of a multidisciplinary approach and the difficulty of diagnosis due to the lack of specific examination methods and insufficient awareness of doctors about this disease are emphasized. The described case demonstrates the need for a personalized approach to managing patients with erythromelalgia to improve their quality of life.
- Open Access
- 26 September 2025
- Published by ECO-Vector LLC in Kazan medical journal
- Vol. 106 (5) , 724-733
Risk factors for thromboembolic events and bleeding in patients with stomach cancer: a cohort study
BACKGROUND: Stomach cancer is associated with systemic disturbances, including impaired hemostasis, which may result in thrombosis and bleeding, significantly affecting the prognosis, quality of life, and risk of fatal outcome. AIM: The study aimed to identify risk factors for thrombosis and bleeding in patients with stomach cancer, assess the prognostic value of existing risk scores using a retrospective analysis of our own findings, and propose ways to improve them. METHODS: The study analyzed medical records of 178 patients with stomach cancer who were treated at Sechenov University in 2021–2023. The medical records were grouped based on two independent variables: the presence of thromboembolic events (25 patients with and 150 patients without thromboembolic events) and the presence of bleeding (23 patients with and 155 patients without bleeding). The outcomes were assessed by examining imaging findings (ultrasound and computed tomography) specified in medical records, which allowed confirming or ruling out thromboembolic events, as well as initial examination findings and discharge summaries following hospitalization for chemotherapy. Qualitative variables are presented as mean ± standard deviation, whereas categorical variables are presented as absolute values and percentages. Intergroup differences were assessed using the Mann–Whitney and Pearson’s chi-squared tests. Significant associations for thromboembolic events and bleeding were identified using multivariate regression analysis. The prognostic value of scores was assessed using ROC analysis (AUC, sensitivity, specificity). SPSS 23.0 was used for statistical analysis. RESULTS: Patients with chronic heart failure had an 11-fold greater risk of thromboembolic events than patients without chronic heart failure (odds ratio [OR] 11.12; 95% confidence interval [CI] 3.14–38.74; p = 0.001). Chronic kidney disease was associated with more than a 5-fold greater risk (OR 5.07; 95% CI 2.02–12.71; p = 0.002), and varicose veins with more than an 8-fold greater risk (OR 8.12; 95% CI 2.87–22.94; p = 0.001). Adding these factors to the Khorana score improved its prognostic value: in ROC analysis, AUC was 0.823 compared to 0.615 at baseline. This indicates a high discriminatory capability of the modified model (AUC 0.8). The REACH score showed a high prognostic value for assessing the risk of bleeding (AUC = 0.738). CONCLUSION: Adding chronic heart failure, chronic kidney disease, and varicose veins to the Khorana score improves its prognostic value for assessing the risk of thromboembolic events. The REACH score was effective in predicting the risk of bleeding.
- 26 September 2025
- Published by ECO-Vector LLC in Kazan medical journal
- Vol. 106 (5) , 724-733
Open AccessRisk factors for thromboembolic events and bleeding in patients with stomach cancer: a cohort study
BACKGROUND: Stomach cancer is associated with systemic disturbances, including impaired hemostasis, which may result in thrombosis and bleeding, significantly affecting the prognosis, quality of life, and risk of fatal outcome. AIM: The study aimed to identify risk factors for thrombosis and bleeding in patients with stomach cancer, assess the prognostic value of existing risk scores using a retrospective analysis of our own findings, and propose ways to improve them. METHODS: The study analyzed medical records of 178 patients with stomach cancer who were treated at Sechenov University in 2021–2023. The medical records were grouped based on two independent variables: the presence of thromboembolic events (25 patients with and 150 patients without thromboembolic events) and the presence of bleeding (23 patients with and 155 patients without bleeding). The outcomes were assessed by examining imaging findings (ultrasound and computed tomography) specified in medical records, which allowed confirming or ruling out thromboembolic events, as well as initial examination findings and discharge summaries following hospitalization for chemotherapy. Qualitative variables are presented as mean ± standard deviation, whereas categorical variables are presented as absolute values and percentages. Intergroup differences were assessed using the Mann–Whitney and Pearson’s chi-squared tests. Significant associations for thromboembolic events and bleeding were identified using multivariate regression analysis. The prognostic value of scores was assessed using ROC analysis (AUC, sensitivity, specificity). SPSS 23.0 was used for statistical analysis. RESULTS: Patients with chronic heart failure had an 11-fold greater risk of thromboembolic events than patients without chronic heart failure (odds ratio [OR] 11.12; 95% confidence interval [CI] 3.14–38.74; p = 0.001). Chronic kidney disease was associated with more than a 5-fold greater risk (OR 5.07; 95% CI 2.02–12.71; p = 0.002), and varicose veins with more than an 8-fold greater risk (OR 8.12; 95% CI 2.87–22.94; p = 0.001). Adding these factors to the Khorana score improved its prognostic value: in ROC analysis, AUC was 0.823 compared to 0.615 at baseline. This indicates a high discriminatory capability of the modified model (AUC 0.8). The REACH score showed a high prognostic value for assessing the risk of bleeding (AUC = 0.738). CONCLUSION: Adding chronic heart failure, chronic kidney disease, and varicose veins to the Khorana score improves its prognostic value for assessing the risk of thromboembolic events. The REACH score was effective in predicting the risk of bleeding.
- Open Access
- 7 August 2025
- Published by Volgograd State Medical University in Journal of Volgograd State Medical University
- Vol. 22 (2) , 126-131
Features of the “Thrombodynamics” test in patients with cancer
Introduction: Thromboembolic complications are one of the leading causes of mortality among cancer patients, significantly worsening their clinical condition and prognosis. Effective diagnostic methods for hypercoagulation and prevention of thromboembolic complications are essential for oncological patients. The “Thrombodynamics” test is an integrative tool that allows for a more precise assessment of the fibrin clot formation process in conditions that closely mimic physiological conditions. Aim: To evaluate the features of hemostasis in patients with cancer using the “Thrombodynamics” test and to identify potential differences in thrombogenic activity depending on the tumor localization. Materials and methods: The study included 100 patients, aged (65 ± 10.6) years, with 75 patients forming the main group (patients with histologically confirmed cancer) and 25 patients forming the control group (healthy individuals). Patients in both groups were matched by gender, age, and comorbidities. The “Thrombodynamics” test was performed according to the standard protocol using the “Thrombodynamics Recorder T-2” system (SDL RT T-2, GemaKor, Moscow, Russia). Results: The results of the study showed that patients with malignant neoplasms have pronounced hypercoagulability, which is confirmed by an increase in the growth rate of the fibrin clot, the initial growth rate and the clot size compared to the control group. Although the differences in the clot growth delay time were insignificant, all other parameters in patients with malignant neoplasms exceeded the reference values, indicating increased thrombogenic activity. И: The Thrombodynamics test shows hypercoagulation in patients with cancer. Further studies are needed to better understand the mechanisms of hypercoagulability in various types of cancer and optimize the methods of TEC prevention in these patients.
- 7 August 2025
- Published by Volgograd State Medical University in Journal of Volgograd State Medical University
- Vol. 22 (2) , 126-131
Open AccessFeatures of the “Thrombodynamics” test in patients with cancer
Introduction: Thromboembolic complications are one of the leading causes of mortality among cancer patients, significantly worsening their clinical condition and prognosis. Effective diagnostic methods for hypercoagulation and prevention of thromboembolic complications are essential for oncological patients. The “Thrombodynamics” test is an integrative tool that allows for a more precise assessment of the fibrin clot formation process in conditions that closely mimic physiological conditions. Aim: To evaluate the features of hemostasis in patients with cancer using the “Thrombodynamics” test and to identify potential differences in thrombogenic activity depending on the tumor localization. Materials and methods: The study included 100 patients, aged (65 ± 10.6) years, with 75 patients forming the main group (patients with histologically confirmed cancer) and 25 patients forming the control group (healthy individuals). Patients in both groups were matched by gender, age, and comorbidities. The “Thrombodynamics” test was performed according to the standard protocol using the “Thrombodynamics Recorder T-2” system (SDL RT T-2, GemaKor, Moscow, Russia). Results: The results of the study showed that patients with malignant neoplasms have pronounced hypercoagulability, which is confirmed by an increase in the growth rate of the fibrin clot, the initial growth rate and the clot size compared to the control group. Although the differences in the clot growth delay time were insignificant, all other parameters in patients with malignant neoplasms exceeded the reference values, indicating increased thrombogenic activity. И: The Thrombodynamics test shows hypercoagulation in patients with cancer. Further studies are needed to better understand the mechanisms of hypercoagulability in various types of cancer and optimize the methods of TEC prevention in these patients.
- Open Access
- 28 February 2025
- Published by NII KPSSZ in Complex Issues of Cardiovascular Diseases
- Vol. 14 (1) , 169-179
IMPLICATION OF CARDIOVASCULAR PATHOLOGY ON THE RISKS OF THROMBOEMBOLIC COMPLICATIONS IN CANCER PATIENTS
HighlightsIt has been demonstrated for the first time that factors such as arterial hypertension, peripheral atherosclerosis, and previous cardiovascular events (heart attack or stroke) significantly increase the risks of both venous and arterial thromboembolic complications in patients with a combination of cardiovascular diseases and malignant neoplasms. The results obtained emphasize the need to review existing scales for assessing the risk of thrombosis in cancer patients and to develop more accurate preventive approaches, including the use of anticoagulant therapy.Background. Cardiovascular disease (CVD) and cancer are leading causes of mortality worldwide. Although CVD and cancer are generally considered isolated diseases, potential cardiotoxicity has been observed in patients receiving chemotherapy or radiation therapy for cancer treatment. Despite the extensive data in the literature, studies examining the relationship between thromboembolic complications, cancer, and CVD remain limited, necessitating further exploration of this issue.Aim. To investigate the association between cardiovascular diseases and cancer concerning the risk of developing and progressing thromboembolic complications.Methods. We retrospectively screened patients with cancer treated between January 1, 2021, and December 31, 2023, at University Clinical Hospital No. 1 of Sechenov University. The study included 877 patients (ages 19 to 93 years, median age 63 years) with histologically confirmed cancer with a high and very high risk of thrombosis (stomach, pancreas, lung, testicles, ovaries, uterus, breast (HER2+ phenotype)).Results. Our findings indicated that patients with higher stages of the primary tumor (T), regional lymph node metastases (N), and distant metastases (M) had a significantly elevated risk of thrombosis. Additionally, the presence of arterial hypertension (p = 0.01), peripheral atherosclerosis (p = 0.001), history of myocardial infarction and stroke (p = 0.001), and type 2 diabetes mellitus (p = 0.009) were identified as significant risk factors.Conclusion. This study demonstrates for the first time that arterial hypertension, peripheral atherosclerosis, diabetes mellitus and a history of myocardial infarction and stroke increase the risks of both venous and arterial venous thromboembolism in patients with cancer and cardiovascular disease. According to the results of the regression analysis, the extent of the primary tumor (T) and the presence of peripheral atherosclerosis appeared to be significant factors.
- 28 February 2025
- Published by NII KPSSZ in Complex Issues of Cardiovascular Diseases
- Vol. 14 (1) , 169-179
Open AccessIMPLICATION OF CARDIOVASCULAR PATHOLOGY ON THE RISKS OF THROMBOEMBOLIC COMPLICATIONS IN CANCER PATIENTS
HighlightsIt has been demonstrated for the first time that factors such as arterial hypertension, peripheral atherosclerosis, and previous cardiovascular events (heart attack or stroke) significantly increase the risks of both venous and arterial thromboembolic complications in patients with a combination of cardiovascular diseases and malignant neoplasms. The results obtained emphasize the need to review existing scales for assessing the risk of thrombosis in cancer patients and to develop more accurate preventive approaches, including the use of anticoagulant therapy.Background. Cardiovascular disease (CVD) and cancer are leading causes of mortality worldwide. Although CVD and cancer are generally considered isolated diseases, potential cardiotoxicity has been observed in patients receiving chemotherapy or radiation therapy for cancer treatment. Despite the extensive data in the literature, studies examining the relationship between thromboembolic complications, cancer, and CVD remain limited, necessitating further exploration of this issue.Aim. To investigate the association between cardiovascular diseases and cancer concerning the risk of developing and progressing thromboembolic complications.Methods. We retrospectively screened patients with cancer treated between January 1, 2021, and December 31, 2023, at University Clinical Hospital No. 1 of Sechenov University. The study included 877 patients (ages 19 to 93 years, median age 63 years) with histologically confirmed cancer with a high and very high risk of thrombosis (stomach, pancreas, lung, testicles, ovaries, uterus, breast (HER2+ phenotype)).Results. Our findings indicated that patients with higher stages of the primary tumor (T), regional lymph node metastases (N), and distant metastases (M) had a significantly elevated risk of thrombosis. Additionally, the presence of arterial hypertension (p = 0.01), peripheral atherosclerosis (p = 0.001), history of myocardial infarction and stroke (p = 0.001), and type 2 diabetes mellitus (p = 0.009) were identified as significant risk factors.Conclusion. This study demonstrates for the first time that arterial hypertension, peripheral atherosclerosis, diabetes mellitus and a history of myocardial infarction and stroke increase the risks of both venous and arterial venous thromboembolism in patients with cancer and cardiovascular disease. According to the results of the regression analysis, the extent of the primary tumor (T) and the presence of peripheral atherosclerosis appeared to be significant factors.
- Open Access
- 9 September 2024
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 20 (4) , 401-408
Nephroprotective and anticoagulant therapy in patients with atrial fibrillation and chronic kidney disease: real-world data
Aim. To assess the compliance of nephroprotective and anticoagulant therapy in patients with atrial fibrillation (AF) and chronic kidney disease (CKD) with modern clinical guidelines.Material and methods. The study included patients with CKD in combination with AF and in sinus rhythm. Clinical characteristics were retrospectively assessed, as were the use of renin-angiotensin system inhibitors (RASi), statins, sodium-glucose transporter type 2 inhibitors (SGLT-2i) and oral anticoagulants (OAC).Results. A total of 464 patients (aged 66-80 years) were divided retrospectively in two subgroups — with and without AF. AF was detected in 210 (45.3%) patients. Patients from the subgroup with AF were significantly older (75 vs 72 years, p=0.001), more often had type 2 diabetes mellitus (T2DM) (28.6% vs 20.5%, p=0.042), coronary artery disease (CAD) (40.5% vs 30.7%, p=0.028) and chronic heart failure (CHF). (57.6% vs 22.8%, p2, p2, p=0.043). In patients with T2DM, SGLT-2i-2 was prescribed in 33.9% of cases, in patients with chronic heart failure with reduced ejection fraction (CHFrEF) — in 68.4% of cases. In 196 patients with AF, DOACs were prescribed, in 10 cases — warfarin.Conclusion. Most patients with CKD receive nephroprotective therapy with RASi and statins according to current KDIGO guidelines. A significant proportion of patients with CHFrEF receive SGLT-2i, but only a third of patients with T2DM and CKD received SGLT-2i therapy.
- 9 September 2024
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 20 (4) , 401-408
Open AccessNephroprotective and anticoagulant therapy in patients with atrial fibrillation and chronic kidney disease: real-world data
Aim. To assess the compliance of nephroprotective and anticoagulant therapy in patients with atrial fibrillation (AF) and chronic kidney disease (CKD) with modern clinical guidelines.Material and methods. The study included patients with CKD in combination with AF and in sinus rhythm. Clinical characteristics were retrospectively assessed, as were the use of renin-angiotensin system inhibitors (RASi), statins, sodium-glucose transporter type 2 inhibitors (SGLT-2i) and oral anticoagulants (OAC).Results. A total of 464 patients (aged 66-80 years) were divided retrospectively in two subgroups — with and without AF. AF was detected in 210 (45.3%) patients. Patients from the subgroup with AF were significantly older (75 vs 72 years, p=0.001), more often had type 2 diabetes mellitus (T2DM) (28.6% vs 20.5%, p=0.042), coronary artery disease (CAD) (40.5% vs 30.7%, p=0.028) and chronic heart failure (CHF). (57.6% vs 22.8%, p2, p2, p=0.043). In patients with T2DM, SGLT-2i-2 was prescribed in 33.9% of cases, in patients with chronic heart failure with reduced ejection fraction (CHFrEF) — in 68.4% of cases. In 196 patients with AF, DOACs were prescribed, in 10 cases — warfarin.Conclusion. Most patients with CKD receive nephroprotective therapy with RASi and statins according to current KDIGO guidelines. A significant proportion of patients with CHFrEF receive SGLT-2i, but only a third of patients with T2DM and CKD received SGLT-2i therapy.
- Open Access
- 27 July 2024
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 29 (3S) , 5790
Management of comorbid patients with chronic kidney disease and decline in renal function: a case report
Chronic kidney disease is one of the most important diseases in comorbid patients with cardiovascular disease. To reduce the risk of cardiovascular and renal complications, such patients should receive renin-angiotensin system inhibitors, statins and sodiumglucose cotransporter 2 inhibitors. However, deterioration of kidney function is still common in these patients, especially in the presence of risk factors. This case illustrates the decline in renal function in a patient with obesity, uncontrolled hypertension, type 2 diabetes and atrial fibrillation. The management strategy for such patients is given.
- 27 July 2024
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 29 (3S) , 5790
Open AccessManagement of comorbid patients with chronic kidney disease and decline in renal function: a case report
Chronic kidney disease is one of the most important diseases in comorbid patients with cardiovascular disease. To reduce the risk of cardiovascular and renal complications, such patients should receive renin-angiotensin system inhibitors, statins and sodiumglucose cotransporter 2 inhibitors. However, deterioration of kidney function is still common in these patients, especially in the presence of risk factors. This case illustrates the decline in renal function in a patient with obesity, uncontrolled hypertension, type 2 diabetes and atrial fibrillation. The management strategy for such patients is given.